Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026 at 12:30 p.m. ET.

A live webcast and limited-time replay will be available in the company Investor section at www.syndax.com.

Argus Feb 5 session

-1.37% close to close Open Argus

Details

News Market Reaction – SNDX

In the Feb 5 session, SNDX declined 1.37%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming visibility for Syndax at the 2026 Guggenheim Emerging Outlook:...

Analysis

This announcement highlights upcoming visibility for Syndax at the 2026 Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, where the CEO will join a fireside chat. It follows a series of substantive updates, including strong Revuforj data at ASH 2025 and preliminary 2025 revenue figures. Investors may focus on how management frames commercial performance, clinical progress, and capital allocation in this forum and subsequent events.

Key Figures

Summit date: February 12, 2026 Fireside chat time: 12:30 p.m. ET

Summit date

February 12, 2026

Guggenheim Emerging Outlook: Biotech Summit fireside chat

Fireside chat time

12:30 p.m. ET

Scheduled start time for Guggenheim Summit fireside chat

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Preliminary 2025 results

   24h Move

   -1.3%

   Unaudited 4Q25 and 2025 revenues and cash position ahead of JP Morgan talk.

2. Jan 07

   Access program expansion

   24h Move

   +8.7%

   Multi-regional managed access program to broaden Revuforj availability outside U.S.

3. Jan 05

   JP Morgan presentation

   24h Move

   -5.1%

   Announcement of CEO presentation at 44th Annual J.P. Morgan Healthcare Conference.

4. Dec 12

   Award and approvals

   24h Move

   -0.2%

   Revuforj named Best New Drug following two FDA approvals in acute leukemias.

5. Dec 08

   Clinical data update

   24h Move

   -1.7%

   Multiple Revuforj abstracts at ASH 2025 with high ORR, CR, and MRD negativity.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 2026 Guggenheim Emerging Outlook: Biotech Summit on Thursday, February 12, 2026, at 12:30 p.m. ET.

A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Syndax (SNDX) CEO Michael A. Metzger speak at the 2026 Guggenheim Biotech Summit?

He will speak on Thursday, February 12, 2026 at 12:30 p.m. ET. According to the company, the appearance is a scheduled fireside chat at the Guggenheim Emerging Outlook: Biotech Summit and is open to webcast viewing for investors.

How can investors watch the Syndax (SNDX) fireside chat on February 12, 2026?

A live webcast will be available via the company Investor section at www.syndax.com. According to the company, the webcast will stream live at 12:30 p.m. ET and a replay will be posted on the site for a limited time.

Will Syndax (SNDX) provide a replay of Michael Metzger's Guggenheim fireside chat?

Yes, a replay will be available for a limited time on the company's investor website. According to the company, the replay follows the live February 12, 2026 webcast and will remain accessible temporarily for investor review.

What is the topic and format of Syndax (SNDX) CEO's presentation at the summit?

The CEO will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026. According to the company, the format is a moderated discussion rather than a formal earnings presentation or press event.

Where can I find details about Syndax (SNDX) participation in the 2026 Guggenheim Biotech Summit?

Details, webcast links, and replay access are posted in the Investor section at www.syndax.com. According to the company, that page will host the live stream on February 12, 2026 and provide a limited-time replay for viewers.